The regents met at 3:45 p.m. in the Riverfront Center. Present were President Schlissel and Regents Behm, Bernstein, Deitch, Ilitch, Newman, Richner, Ryder Diggs and White. Also present were Chancellor Borrego, Vice President Churchill, Vice President Harper, Executive Vice President Hegarty, Vice President Hu, Chancellor Little, Vice President Lynch, Vice President May, Interim Vice President Michels, Provost Pollack, Executive Vice President Runge, and Vice President Wilbanks.

Call to Order and President’s Opening Remarks

President Schlissel thanked Chancellor Susan Borrego and the Flint team for hosting the October meeting. He spoke of UM-Flint’s excellence in engaged learning and applied research, evidenced with the recent award of a $400,000 grant by the U.S. Economic Development Administration to establish a University Center for Community and Economic Development. The center will support economic development efforts for the entire region and expand on the success of UM-Flint’s Innovation Incubator.

He congratulated two UM faculty members elected to the National Academy of Medicine: Kathleen Collins, professor, Department of Microbiology and Immunology, and senior scholar in the A. Alfred Taubman Medical Research Institute; and Roger Cone, Mary Sue Coleman director of the UM Life Sciences Institute, and professor, Department of Molecular and Integrative Physiology.
President Schlissel sadly reported on the passing of Dr. Robert Winfield, executive director of University Health Service, and the first chief health officer who was a friend and colleague for 42 years. He spoke of Dr. Winfield’s bedside manner and responsiveness, his intellect and vision and his leadership in helping to develop a smoke free campus, M-Healthy health and wellness programs, and pandemics and severe weather response plans. He said, “We will forever miss his warmth, his vision, his personal generosity, and his amazing passion for our community. I express my condolences to his family and his many friends and loved ones.”

President Schlissel summarized progress on the unveiling of the University of Michigan Strategic Plan for Diversity, Equity and Inclusion for the Ann Arbor campus. The future of the university will involve embracing the values of diversity, equity and inclusion. He described the importance of values, including a dedication to academic excellence for the public good that is inseparable from a commitment to diversity, equity and inclusion, and that everyone has an opportunity to contribute, to benefit, and to feel welcome. He said that the plan is also a pledge to those who have had painful experiences at UM, that implementation begin immediately and will be ongoing.

President Schlissel brought forward a supplemental item for a new senior leadership position, the first-ever chief diversity officer who will serve as principal advisor to the president and executive officers on DE&I, and recommended the appointment of Rob Sellers as Chief Diversity Officer.

President Schlissel continued and announced recommendations for honorary degrees for Winter Commencement. Ron Carter is a renowned jazz bassist, a jazz studies program faculty member at Julliard, and the inventor of the piccolo base. A native of Ferndale, Mr. Carter performed with the Ann Arbor Youth Symphony and graduated from Cass Tech in Detroit. His
Grammy-award winning career includes more than 2,200 recording credits, 25 of which were with the Miles Davis Quintet. Mr. Carter is recommended for an Honorary Doctor of Music.

Maxine Frankel is a UM alumna, Detroit native, philanthropist, and supporter of the arts who has made an impact in the Museum of Art and the University Musical Society. She received the first-ever honorary degree from the Cranbrook Academy of Art in Bloomfield in recognition of her work on education in the arts. She co-chaired the Michigan Difference National Leadership Campaign and is a member of the UM Bicentennial Advisory Committee. She is recommended for an Honorary Doctor of Fine Arts.

University of Miami President Julio Frenk is a visionary leader in global public health and a UM alumnus, who has worked with the World Health Organization and served as Dean of the Harvard School of Public Health. As Mexico’s minister of health from 2000 to 2006, he introduced a universal insurance program that extended coverage to 50 million people. Dr. Frenk will deliver the commencement address, and is recommended for an Honorary Doctor of Laws.

Michael M. E. Johns has a long career in academic medicine, distinguished service as an innovator, mentor, policy advisor, education leader and surgeon specializing in head and neck cancers. He earned an M.D. from the UM Medical School, and was the dean of the Johns Hopkins University School of Medicine and then the executive vice president for health affairs at Emory University before returning to Michigan to serve as interim executive vice president for Medical Affairs from 2014-2015. Upon winning the 2015 National Physician of the Year Award for Lifetime Achievement from Castle Connolly, he said, “The most important thing we can do in our careers is to realize that our greatest contribution is in helping others to keep the winds of change blowing.” Dr. Johns is recommended for an Honorary Doctor of Science.
President Schlissel spoke of the February Board action to establish the position of vice president for information technology and chief information officer. The position reports to the president, is a member of the executive leadership team, and oversees information technology strategy, systems and services for the university.

He stressed that the importance of information and technology to our mission and brought forward a supplemental item recommending the appointment of Kelli Trosvig to the position of vice president for information technology and chief information officer. She is currently at the University of Washington where her experience includes leadership positions in UW’s academic medical center.

President Schlissel proudly announced a transformative gift from Frances and Kenneth A. Eisenberg and their family of $10.75 million to the UM Depression Center, to develop personalized treatments for clinical depression, bipolar disorder and related illnesses. He said, “The Eisenberg gift will help advance the work of the Depression Center, which was one of the world’s first comprehensive centers established to fight depression and its associated stigma.” He then brought forward a supplement item for the Frances and Kenneth Eisenberg Professorship in Depression and Neurosciences, recommending Dr. Srijan Sen, a leading expert in the biology of stress and depression as the inaugural Eisenberg Professor.

He noted that Election Day is on Tuesday, Nov. 8 and urged everyone to get out and vote, and turned the meeting over to Chancellor Borrego to introduce the presentation.

**Presentation: Physical Therapy**

Chancellor Borrego thanked President Schlissel and welcomed everyone to Flint and introduced Professor Allon Goldberg, director of the UM-Flint Department of Physical Therapy saying, “Our physical therapy program sustains a trailblazing history of excellence offering the
first master’s of Physical Therapy in 1990, the first doctor in 2002, and the first Ph.D. in 2014. Last year the program became the first to offer a credentialed neurologic residency alongside the pediatric and orthopedic residencies.”

Dr. Goldberg said the program moved to Flint in 1982 from Ann Arbor, and is the only academic physical therapy department in the UM system. The program has a long history of leading the profession in the state of Michigan as it currently holds the state’s only Ph.D. program, a new program that prepares students for careers in academia and research. He spoke of opportunities for students within service learning, and the Physical Therapy Heart Pro-Bono Clinic serving the uninsured and underserved in the community. In 2016, the U.S. News and World Report ranked the program 53rd out of more than 200 programs, the only Michigan program in the top 100.

Committee Reports

Finance, Audit, and Investment Committee. Regent White, chair, reported that she and Regent Bernstein met with Kevin Hegarty, executive vice president and chief financial officer, Nancy Hobbs associate vice president for finance, Cheryl Soper university controller and director of financial operations, and representatives from PricewaterhouseCoopers to discuss the University’s fiscal 2016 financial statements and the results of the related external audit. Executive Vice President Hegarty provided the FAI committee an overview of the efforts taken by Procurement Services to build a diverse supply base for the university and reviewed the university’s debt and current debt strategy.

The Committee also received an update from the University’s Chief Investment Officer, Erik Lundberg, regarding the university’s investment performance for fiscal year 2016. He reported that the return on investment for the university’s Long Term Portfolio, which the
university’s endowment funds are principally invested in, was minus -1.36 percent for the fiscal year, which is in the top quartile of performance when compared to other college and university endowments for the same period.

The 10-year annualized return of 6.7 percent places UM in the top decile for long-term investment performance among university endowments and has been more than sufficient to sustain and grow the endowment in real terms net of spending. Fiscal year 2016 distributions from the endowment exceeded $300 million for the first time in the university’s history. Distributions from the endowment over the past 15 years totaled more than $3.4 billion.

The value of the endowment was $9.7 billion as of June 30, 2016, a decline from $10.0 billion in the previous year. The change in market value from the prior year was due to the small investment loss and distributions, which was partially offset by new endowment gifts.

Consent Agenda

Minutes. Vice President Churchill submitted for approval the minutes of the meeting of September 15, 2016.


Litigation Report. Vice President Lynch had no report.

Research Report. Vice President Hu submitted the Report of Projects Established, July 1 2015 – September 30, 2016. He reported that they reached a new research record of $1.39 million, and said more details will be available in February 2017.

University of Michigan Health System. Executive Vice President Runge had no report.

Student Life. Vice President Harper had no report.
University of Michigan-Dearborn. Chancellor Little reported 2,400 new students and a record number of new freshman on the Dearborn campus. He noted successful collaboration between the UM Enrollment Services Office and the HAIL Scholars program with 75 of these scholars choosing to attend UM-Dearborn.

University of Michigan-Flint. Chancellor Borrego said, “It has been a year of lessons and a year of tests in capacity and priorities. Through it all, this campus exhibited its absolute devotion to making a difference in our students’ lives and in our community. We are proud to be here.” The UM-Flint is a campus of 10,000 in a community of less than 100,000, has a $70 million fiscal impact on Genesee County, and has a highly a diverse student body.

Chancellor Borrego spoke of the investment of $39 million to expand the Murchie Science Building adding more innovative classroom and research space for both faculty and students. She said that UM-Flint celebrated its 60th anniversary year and that 40,000 students have graduated, many of whom still live in the Flint community.

Central Student Government Report.

Flint Student Government President Menusha Arumugam spoke of the rich, diverse student body on the Flint campus. Current initiatives include forming a pep band to perform at community events and creating a sports wall showcasing the contributions of their athletic teams. Student leaders have brought students together to talk about current events, including the Black Lives Matter movement. She said, “If we truly are leaders and the best, we must work together” and said that the Student Government presidents from all three campuses have been collaborating to bridge the gap between their campuses.

Central Student Government (CSG) President David Schafer thanked the Flint campus for its leadership. He noted the recent events on the Ann Arbor campus that made students feel
unsafe and unwelcome. He said, “When any member is made to feel that way, it hurts all of us. The Michigan I know is decent, generous, inclusive and tolerant. But without action those are just words.” He applauded the administration on its timely response, including a community dialogue with students. He has attended the launch of the University’s DE&I strategic plan, and said it included student participation in the implementation phase. He also spoke of the initiative in collaboration with the Office of University Development and Events, to develop the Leadership Engagement Scholarship, to reduce the cost for taking a leadership role in extra curricular activities. He also showed a brief video. To date, the fund has pledges of $100,000 with a goal of $500,000. He thanked Julie Sousa for her inaugural gift and encouraged the regents to support the scholarship fund.

Regent Newman applauded CSG President Schafer on his presentation and said, “What you are doing is right and you will attract donors. I look forward to helping you grow this fund so all students from different socioeconomic backgrounds will have a chance. Thank you for bringing this forward and congratulations.”

Regent Bernstein said, “I learned a lot outside of the classroom and students will probably say the same thing. I am looking forward to working on this to help expand those opportunities.”

**Voluntary Support.** Vice President May submitted reports for September 2016.

**Personnel Actions/Personnel Reports.** Provost Pollack presented a number of personnel actions and reports.

**Retirement Memoirs.** Vice President Churchill submitted two faculty retirement memoirs.

**Memorials.** There were no deaths reported this month.
**Degrees.** Provost Pollack presented the August 2016 final list of degrees and the recommendations for Honorary Degrees.

**Approval of Consent Agenda.** On a motion by Regent Bernstein, seconded by Regent Ilitch, the regents unanimously approved the consent agenda, including the supplemental personnel items.

Executive Vice President Runge talked about the Eisenberg gift, saying, “It enhances efforts by expanding research projects and establishing emergence scholars awards. It allows us to position ourselves in the forefront.”

Vice President May said, “Kenneth and Frances Eisenberg serve on five different committees, supporting multiple schools and colleges and the University. Their adult children are also deeply involved.”

Regent Deitch noted their previous $5 million gift to the Department of History. He said, “Dr. John Greden created the Depression Center out of nothing. This gift will only further his great work and research done to help treat depression and bipolar diseases.”

**Alternative Asset Commitments and Public equity Investment**

Vice President Hegarty reported on the commitments of £24.76 million (~$32.20 million) to CBPE Capital IX, L.P.; $23 million to Andreessen Horowitz Fund V, L.P. and Andreessen Horowitz Parallel Fund V, L.P.; $50 million to Acadia Investors V, INC.; and $20 million to PS Latin America Offshore, LTD.

**Alternative Asset Commitment**

On a motion by Regent White, seconded by Regent Newman, the regents unanimously approved the commitment of $25 million from the University’s Long Term Portfolio to Union Capital Equity Partners II, L.P.
Alternative Asset Commitment

On a motion by Regent Behm, seconded by Regent Richner, the regents unanimously approved the commitment of up to SEK 345 million (~$40 million) from the University’s Long Term Portfolio to Summa Equity I, L.P.

Alternative Asset Commitment

On a motion by Regent White, seconded by Regent Richner, the regents unanimously approved the commitment of $10 million from the University’s Long Term Portfolio to TI Platform Fund I, L.P.

Absolute Return

On a motion by Regent Ilitch, seconded by Regent Behm, the regents unanimously approved the commitment of $50 million from the University’s Long Term Portfolio to Sabal Debt Opportunities Fund, L.P.

University of Michigan Financial Statements for the Year Ended June 30, 2016

On a motion by Regent Ilitch, seconded by Regent Behm, the regents unanimously approved the adoption of the University’s consolidated audited financial statements as submitted.

Bond Resolution (INSERT RESOLUTION)

On a motion by Regent Behm, seconded by Regent Ilitch, the regents unanimously approved the adoption of the resolution authorizing the Executive Vice President and Chief Financial Officer or the Associate Vice President for Finance, or the Treasurer to:

- Develop the terms, negotiate and execute the legal documentation for the financing with the assistance of the underwriter and outside legal counsel.
- Obtain and approve a final proposal for the bonds.
- Obtain and accept a final proposal for any swaps and any liquidity agreements required for the University’s variable rate debt, and execute and deliver the required documentation for the transaction.
North Campus Research Complex Buildings 20 and 25 Laboratory Renovation

On a motion by Regent Bernstein, seconded by Regent Behm, the regents unanimously approved the $78,500,000 North Campus Research Complex Buildings 20 and 25 laboratory renovation project as described and authorized commissioning SmithGroupJJR for its design.

Joseph Aldrich and Marguerite Knowlton Bursley Hall Window Replacement

On a motion by Regent Behm, seconded by Regent Ilitch, the regents unanimously approved the $4,900,000 Joseph Aldrich and Marguerite Knowlton Bursley Hall window replacement project as described, and authorized issuing the project for bids and awarding construction contracts provided that bids are within the approved budget.

UMHHC Taubman Health Care Center Central Cardiac Monitoring

On a motion by Regent Behm, seconded by Regent Richner, the regents unanimously approved the $5,000,000 University of Michigan Hospitals and Health Centers A. Alfred Taubman Health Care Center Central Cardiac Monitoring project as described, authorized commissioning the architectural firm of Niagara Murano for its design, and authorized issuing the project for bids and awarding construction contracts provided that bids are within the approved budget.

UMHHC University Hospital South Faculty Office Renovations

On a motion by Regent White, seconded by Regent Richner, the regents unanimously approved the $8,200,000 University of Michigan Hospitals and Health Centers University Hospital South Faculty Office renovation project as described, authorized commissioning the architectural firm of Tower Pinkster Titus Associates for its design, and authorized issuing the project for bids and awarding construction contracts provided that bids are within the approved budget.
UMHHC University Hospital Interventional Radiology Equipment Replacement

On a motion by Regent Newman, seconded by Regent Richner, the regents unanimously approved the $3,500,000 University of Michigan Hospitals and Health Centers University Hospital Interventional Radiology Equipment replacement project as described, authorized commissioning the architectural firm of Integrated Design Solutions for its design, and authorized issuing the project for bids and awarding construction contracts provided that bids are within the approved budget.

Conflicts of Interest Items

On a motion by Regent Bernstein, seconded by Regent Newman, the regents approved the conflict of interest items that fall under the State of Michigan Conflict of Interest Statute.

The following information is provided in compliance with statutory requirements:

Authorization for the University to transact with Sherm’s Instrument Repair

An agreement with Sherm’s Instrument Repair to extend the previously approved purchase for musical instrument repair and maintenance services through 2018 was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its UM-Flint Department of Music and Sherm’s Instrument Repair.

2. The agreement is for musical instrument repair and maintenance services through 2018 at an annual cost of $5,000 and a total cost not to exceed $15,000. Sherm’s Instrument Repair will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in procurement services standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Joseph Wright is the owner of Sherm’s Instrument Repair.

Authorization for the University to transact with Jazz Pie Music

An agreement with Jazz Pie Music for musical performances at the Law School events from 2016 through 2018 was approved.
1. Parties to the agreement are the Regents of the University of Michigan and its Law School and Jazz Pie Music.

2. The agreement is for musical performances from 2016 through 2018 at a total cost not to exceed $3,500. Jazz Pie Music will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in procurement services standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employees Christopher Smith, James Dapogny, and Roderick McDonald are band members of Jazz Pie Music.

Authorization for the University to transact with Food Allergy and Research Education (FARE)

An agreement with Food Allergy and Research Education (FARE) to sponsor the 2016 FARE Walk for Food Allergy was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Division of Allergy and Clinical Immunology and FARE.

2. The agreement is a sponsorship for the 2016 FARE Walk for Food Allergy in the amount of $5,000. FARE will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in procurement services standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee James R. Baker Jr. is the CEO of FARE.

Subcontract Agreement between the University of Michigan and ATGC, Inc.

A subcontract agreement with ATGC, Inc. to fund a NIH (prime) STTR Phase I project entitled: “A Nanoparticle Delivery System for CRISPR/Cas9 Based Therapeutics” (ORSP# 17-PAF01051) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and ATGC, Inc.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $90,000. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Dr. Yuqing Chen and Jie Xu are part owners of ATGC, Inc.

**Subcontract Agreement between the University of Michigan and CubeWorks, Inc.**

A subcontract agreement with CubeWorks, Inc. to fund a National Science Foundation (prime) SBIR Phase II project entitled “Millimeter-Scale Wireless Sensor Node for Intracranial Pressure Monitoring” (ORSP# 16-PAF07104) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Electrical Engineering and Computer Science, and CubeWorks, Inc.
2. The terms of the agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $251,392. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Dennis Sylvester, David Blaauw, David Wentzloff, Prabal Dutta, and Zhiyoong Foo are part owners with equity of CubeWorks, Inc.

**Research Agreement between the University of Michigan and Eli Lilly and Company**

A research agreement with Eli Lilly and Company to enter into a contract agreement entitled “Flow Photocatalysis: Visible Light Photoredox Catalysis” (ORSP# 16-PAF02841) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Chemistry and Eli Lilly and Company.
2. The terms of the agreement conform to University policy. The period of performance for the project is approximately three (3) years. The amount of funding support will not exceed $562,650. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that the University of Michigan employee Marschall Runge is a paid member of the Board of Directors of Eli Lilly and Company.
Option Agreement between the University of Michigan and Global Health Management Research Core, LLC

An option agreement with Global Health Management Research Core, LLC to option from the University of Michigan the University’s rights associated with the following technology: UM OTT File No. 5046, entitled: “Next Generation Health Risk Appraisal System” was approved.

1. Parties to the agreement are the Regents of the University of Michigan and Global Health Management Research Core, LLC

2. Agreement terms include granting Global Health Management Research Core, LLC a non-exclusive option. Global Health Management Research Core, LLC will pay a royalty on sales. The University may receive equity in Global Health Management Research Core, LLC, along with the right to purchase more equity. The University will retain ownership of the optioned technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University of employees, is obligated or contemplated under the agreement. Standard disclaimers of warrantees and indemnification apply, and the agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from University of Michigan employees Louis Tze-Ching Yen, Lingzhi Chen, Jerome Schatzle, Wei Zhou, Jin Park, and Lixin Yan’s ownership interest in Global Health Management Research Core, LLC.

Research Agreement between the University of Michigan and IFM Therapeutics, Inc.

A research agreement with IFM Therapeutics, Inc. to fund a project entitled: “Analyzing Small Molecules that Modulate Targets in the Innate Immune System” (ORSP# 17-PAF01076) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Pediatrics, and IFM Therapeutics, Inc.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately four (4) years. The amount of funding support will not exceed $1,240,000. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Anthony Opipari Jr., Luigi Franchi, and Gary Glick are part owners of IFM Therapeutics, Inc.

Research Agreement between the University of Michigan and IFM Therapeutics, Inc.

A research agreement with IFM Therapeutics, Inc. to fund a project entitled: “Mechanistic Studies of MLRP1 Protein Function” (ORSP# 17-PAF01790) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Pediatrics, and IFM Therapeutics, Inc.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately six (6) months. The amount of funding support will not exceed $96,687. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Anthony Opipari Jr., Luigi Franchi, and Gary Glick are part owners of IFM Therapeutics, Inc.

Subcontract Agreement between the University of Michigan and Mekanistic Therapeutics LLC

A subcontract agreement with Mekanistic Therapeutics LLC to fund a NIH (prime) STTR Phase I project entitled “STTR Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer” (ORSP# 17-PAF01252) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Radiology, and Mekanistic Therapeutics LLC

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $88,767. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Judith S. Leopold and Christopher E. Whitehead are part owners of Mekanistic Therapeutics LLC.
Subcontract Agreement between the University of Michigan and NOTA Laboratories LLC

A subcontract agreement with NOTA Laboratories LLC to fund a National Institutes of Health (prime) SBIR Phase II project entitled “S-Nitrosothiol-Based Rinse/Aerosol Solutions for Treatment/Prevention of Rhinosinusitis” (ORSP# 17-PAF00944) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Chemistry, and NOTA Laboratories LLC

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $82,175. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Mark E. Meyerhoff, Mark A. Zacharek, and Marc B. Hershenson are part owners of NOTA Laboratories LLC.

Subcontract Agreement between the University of Michigan and NOTA Laboratories LLC

A subcontract agreement with NOTA Laboratories LLC to fund a National Institutes of Health (prime) STTR Phase I project entitled “Low Molecular Weight Arginine-Rich Peptides Derived from Protamine as Agents to Increase Sinonasal Nitric Oxide Levels in Treatment/Prevention of Rhinosinusitis” (ORSP# 17-PAF01075) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Chemistry, and NOTA Laboratories LLC

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $31,488. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Mark E. Meyerhoff, Mark A. Zacharek, and Marc B. Hershenson are part owners of NOTA Laboratories LLC.
Research Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A research agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US” (ORSP #16-PAF06572) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $2,550, unless the contract is amended to provide the patient with further treatment with TH-302. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.

Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “SARC Concept Review Committee Chair” (ORSP #16-PAF06801) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $6,016. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.
Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “Year 5 Funding: Tissue and Pathology Core – SARC Sarcoma Spore” (ORSP #16-PAF07879) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Pathology, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $88,572. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.

Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “Tissue and Pathology Core – SARC Sarcoma Spore” (ORSP #17-PAF00857) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Pathology, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $252,000. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.
Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “SARC Sarcoma SPORE” (ORSP #17-PAF00951) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Pathology, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $79,235. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.

Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “SARC Sarcoma SPORE” (ORSP #17-PAF00987) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $145,770. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.
Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration (the “Company”) to enter into a contract agreement entitled: “SARC Sarcoma SPORE – Project 2” (ORSP #17-PAF01731) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $86,070. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.

Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “SARC Sarcoma SPORE – Project 3” (ORSP #17-PAF01732) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $180,755. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.
Services Agreement between the University of Michigan and Sarcoma Alliance for Research through Collaboration

A services agreement with Sarcoma Alliance for Research through Collaboration to enter into a contract agreement entitled: “SARC Sarcoma SPORE – Core C” (ORSP #17-PAF01822) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Sarcoma Alliance for Research through Collaboration.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $145,770. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and CEO of Sarcoma Alliance for Research through Collaboration.

Subcontract Agreement between the University of Michigan and Stryd

A subcontract agreement with Stryd to fund a National Science Foundation (prime) STTR Phase I project entitled “Providing Real Time Feedback on the Bone Density Implications of Physical Exercise to Osteoporosis and Osteopenia Patients” (ORSP# 16-PAF07909) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Electrical Engineering and Computer Science, and Stryd.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately six (6) months. The amount of funding support will not exceed $33,750. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Robert Dick is a part owner of Stryd.
Subcontract Agreement between the University of Michigan and Stryd

A subcontract agreement with Stryd to fund a National Science Foundation (prime) STTR Phase I project entitled “Using Mechanical Power for Cardiac Risk Stratification and Rehabilitation” (ORSP# 16-PAF07910) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Electrical Engineering and Computer Science, and Stryd.
2. The terms of the agreement conform to University policy. The period of performance for the project is approximately six (6) months. The amount of funding support will not exceed $33,750. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employee Robert Dick is a part owner of Stryd.

Subcontract Agreement between the University of Michigan and Therapeutic Systems Research Laboratories, Inc.

A subcontract agreement with Therapeutic Systems Research Laboratories, Inc. to fund a NIH (prime) SBIR Phase I project entitled “A Distraction Osteogenesis-Enabling therapeutic Solution for Mandibular Craniofacial Reconstructive Surgery” (ORSP# 17-PAF00989) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Plastic Surgery, and Therapeutic Systems Research Laboratories, Inc.
2. The terms of the agreement conform to University policy. The period of performance for the project is approximately three (3) years. The amount of funding support will not exceed $574,906. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Dr. Gordon Amidon and Dr. Gregory Amidon are either part owner or have a leadership role in Therapeutic Systems Research Laboratories, Inc.
Subcontract Agreement between the University of Michigan and Therapeutic Systems Research Laboratories, Inc.

A subcontract agreement with Therapeutic Systems Research Laboratories, Inc. to fund a NIH (prime) R01 project entitled “Preclinical Development of Genetically Modified Lectin for Treatment of a Broad-Range of Viral Infections” (ORSP# 17-PAF01514) was approved.

1. Parties to the agreement are the Regents of the University of Michigan and its Department of Internal Medicine, and Therapeutic Systems Research Laboratories, Inc.

2. The terms of the agreement conform to University policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $2,330,106. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest reviews will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Dr. Gordon Amidon and Dr. Gregory Amidon are either part owner or have a leadership role in Therapeutic Systems Research Laboratories, Inc.

Revisions to the Regents’ Bylaws

On a motion by Regent White, seconded by Regent Bernstein, the regents unanimously approved the revisions to the University of Michigan Regents’ Bylaws 2.13 as presented.

Supplemental Agenda: UM-Flint School of Nursing

Chancellor Borrego said, “It is with great honor that I ask for your support in the creation of a School of Nursing at the University of Michigan-Flint. Our Department of Nursing has educated and trained nearly 3,000 nurses and nurse practitioners in its 45-year history. More than 19% of our students are nursing or pre-nursing students and more than 24% of our 1,223 undergraduate degrees last year were in Nursing. The creation of a School of Nursing will give greater visibility to this program and it is consistent with other institutions of higher learning.

24
This focus on Nursing also reflects the importance of the field, which is one of the fastest growing occupations in the state.”

On a motion by Regent Richner, seconded by Regent Behm, the regents unanimously approved the creation of the University of Michigan-Flint School of Nursing.

Regent Behm said, “As a son of a nurse, I really support this.”

Regent Ilitch said, “This is phenomenal and wonderful. It is great for this school and for the community. You have donated thousands of hours and I am super excited for you. Congratulations!”

**Public Comment**

The regents heard public comments from, student, Joshua Denzler, on the student life unions and recreational sports renovations.

**Adjournment**

The meeting was adjourned at 5:00 p.m. The next meeting will take place on December 8, 2016 on the Ann Arbor Campus.